[Skip to Content]
[Skip to Content Landing]
Citations 0
Evidence-Based Dermatology: Research Commentary
September 2002

Alefacept for Psoriasis: Promising Drug, Open Questions

Author Affiliations
 

MichaelBigbyMDRosamariaCoronaDSc, MDDamianoAbeniMD, MPHPaoloPasquiniMD, MPHMoysesSzkloMD, MPH, DrPHHywelWilliamsMD

Arch Dermatol. 2002;138(9):1238-1240. doi:10.1001/archderm.138.9.1238

Alefacept (Amevive; Biogen Inc, Cambridge, Mass) is a fusion protein that binds to the CD2 receptor on lymphocytes, blocking its interaction with lymphocyte function–associated antigen-3 on antigen-presenting cells. Most lymphocytes in psoriatic lesions are memory effector (CD4+CD45RO+ and CD8+CD45RO+) T cells showing up-regulation of CD2 on their cell surface. By binding preferentially to these cells in psoriasis, alefacept may inhibit their activation and may reduce disease activity.

First Page Preview View Large
First page PDF preview
First page PDF preview
×